Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 22Ovarian Neoplasms 16Fallopian Tube Neoplasms 8Breast Neoplasms 5Recurrence 4Carcinoma, Ovarian Epithelial 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Progesterone Resistance 2Pancreatic Neoplasms 2Endometrial Hyperplasia 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Peritoneal Neoplasms 1Ovarian Cysts 1Obesity 1Neoplasms by Site 1Neoplasms 1Low-Grade Serous Ovarian Cancer 1Low Grade Serous Ovarian Carcinoma 1Low Grade Serous Ovarian Cancer 1Leiomyosarcoma 1Hydatidiform Mole 1Hereditary Sensory and Autonomic Neuropathies 1Hereditary Breast and Ovarian Cancer Syndrome 1Head and Neck Neoplasms 1Gestational Trophoblastic Disease 1

Interventions

camrelizumab 1Surgical Procedures, Operative 1Paclitaxel 1ON123300 1Letrozole 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrioid Endometrial Cancer × Letrozole × Gynecologic × Clear all
NCT05705505 2023-12-12

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Traws Pharma, Inc.

Phase 1/2 Unknown
60 enrolled
Gynecologic

Endometrioid Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡